TherapeuticsMD, Inc. (TXMD): Price and Financial Metrics
TXMD Price/Volume Stats
| Current price | $1.90 | 52-week high | $4.73 |
| Prev. close | $1.92 | 52-week low | $1.86 |
| Day low | $1.87 | Volume | 5,701 |
| Day high | $1.91 | Avg. volume | 21,062 |
| 50-day MA | $2.23 | Dividend yield | N/A |
| 200-day MA | $2.73 | Market Cap | 21.91M |
TXMD Stock Price Chart Interactive Chart >
TherapeuticsMD, Inc. (TXMD) Company Bio
TherapeuticsMD, Inc. operates as a womens health care product company. The company manufactures and distributes prescription and over-the-counter product lines, including prenatal vitamins, iron supplements, vitamin D supplements, and natural menopause relief products under the vitaMedMD brand, as well as duplicate formulations of its prescription prenatal vitamins products under the BocaGreenMD Prena1 name. The company was founded in 2008 and is based in Boca Raton, Florida.
Latest TXMD News From Around the Web
Below are the latest news stories about THERAPEUTICSMD INC that investors may wish to consider to help them evaluate TXMD as an investment opportunity.
TherapeuticsMD Announces Third Quarter 2023 Financial ResultsBOCA RATON, Fla., November 14, 2023--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the third quarter ended September 30, 2023. |
TherapeuticsMD Announces Second Quarter 2023 Financial ResultsBOCA RATON, Fla., August 14, 2023--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the second quarter ended June 30, 2023. |
TherapeuticsMD Announces First Quarter 2023 Financial ResultsBOCA RATON, Fla., May 15, 2023--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2023. |
All You Need to Know About TherapeuticsMD (TXMD) Rating Upgrade to BuyTherapeuticsMD (TXMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model TransitionBOCA RATON, Fla., April 07, 2023--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2022. |
TXMD Price Returns
| 1-mo | -15.56% |
| 3-mo | -16.30% |
| 6-mo | -5.47% |
| 1-year | -46.18% |
| 3-year | -96.89% |
| 5-year | -99.08% |
| YTD | -15.56% |
| 2023 | -59.75% |
| 2022 | -68.55% |
| 2021 | -70.62% |
| 2020 | -50.00% |
| 2019 | -36.48% |
Continue Researching TXMD
Here are a few links from around the web to help you further your research on TherapeuticsMD Inc's stock as an investment opportunity:TherapeuticsMD Inc (TXMD) Stock Price | Nasdaq
TherapeuticsMD Inc (TXMD) Stock Quote, History and News - Yahoo Finance
TherapeuticsMD Inc (TXMD) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...